Brief: Bio-Rad Q4 Adjusted EPS USD 2.9 Vs. IBES Estimate USD 2.87
13/02/2025 21:20
Feb 13 (Reuters) - Bio-Rad Q4 EPS USD -25.57. * Q4 EBIT margin 8.7% * Q4 sales USD 667.5 million vs. IBES estimate USD 679.3 million * Q4 gross margin 51.2% * Q4 net income USD -715.8 million * outlook FY adjusted revenue growth 1.5-3.5%
Recent news on Bio-Rad Laboratories
See all newsBio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Bio-Rad Laboratories On July 31, Initiated Restructuring Plan - SEC Filing
Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Brief: Bio-Rad Q2 Net Income USD 371.4 Million
Activist investors make bigger push for campaigns in H1, seek more M&A